首页> 外文期刊>International Journal of Pharmaceutics >Production of polymeric micelles by microfluidic technology for combined drug delivery: Application to osteogenic differentiation of human periodontal ligament mesenchymal stem cells (hPDLSCs)
【24h】

Production of polymeric micelles by microfluidic technology for combined drug delivery: Application to osteogenic differentiation of human periodontal ligament mesenchymal stem cells (hPDLSCs)

机译:通过微流控技术生产聚合物胶束以实现联合给药:在人牙周膜间充质干细胞(hPDLSCs)的成骨分化中的应用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The current paper reports the production of polymeric micelles (PMs), based on pluronic block-copolymers, as drug carriers, precisely controlling the cellular delivery of drugs with various physico-chemical characteristics. PMs were produced with a microfluidic platform to exploit further control on the size characteristic of the PMs. PMs were designed for the co-delivery of dexamethasone (Dex) and ascorbyl-palmitate (AP) to in vitro cultured human periodontal ligament mesenchymal stem cells (hPDLSCs) for the combined induction of osteogenic differentiation. Mixtures of block-copolymers and drugs in organic, water miscible solvent, were conveniently converted in PMs within microfluidic channel leveraging the fast mixing at the microscale. Our results demonstrated that the drugs can be efficiently co-encapsulated in PMs and that different production parameters can be adjusted in order to modulate the PM characteristics. The comparative analysis of PM produced by microfluidic and conventional procedures confirmed that the use of microfluidics platforms allowed the production of PMs in a robust manner with improved controllability, reproducibility, smaller size and polydispersity. Finally, the analysis of the effect of PMs, containing Dex and AP, on the osteogenic differentiation of hPDLSCs is reported. The data demonstrated the effectiveness and safety of PM treatment on hPDLSC. In conclusion, this report indicates that microfluidic approach represents an innovative and useful method for PM controlled preparation, warrant further evaluation as general methodology for the production of colloidal systems for the simultaneous drug delivery.
机译:本论文报道了以普鲁尼克嵌段共聚物为基础的聚合物胶束(PMs)的生产,该聚合物作为药物载体,可精确控制具有各种理化特性的药物的细胞递送。使用微流体平台生产PM,以进一步控制PM的尺寸特征。 PM被设计用于地塞米松(Dex)和抗坏血酸棕榈酸酯(AP)向体外培养的人牙周膜间充质干细胞(hPDLSCs)的共同递送,从而共同诱导成骨分化。利用微尺度的快速混合,可以轻松地将嵌段共聚物和药物在有机,水混溶溶剂中的混合物转化为微流体通道内的PM。我们的结果表明,这些药物可以有效地共包封在PM中,并且可以调节不同的生产参数以调节PM特性。通过微流控和常规程序生产的PM的对比分析证实,使用微流控平台可以以稳健的方式生产PM,并具有可控性,可重复性,更小的尺寸和多分散性。最后,报道了含有Dex和AP的PMs对hPDLSCs成骨分化的影响的分析。数据证明了PM治疗hPDLSC的有效性和安全性。总之,本报告表明,微流控方法代表了PM控制制剂的一种创新且有用的方法,值得进一步评估,作为生产同时给药的胶体系统的一般方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号